Merus N V (MRUS)

01:11 AM

Why Merus N.V. stock is on top investor watchlistsHigh-impact stock picks - jammulinksnews.com

01:11 AM

12:30 PM

How high can Merus N.V. stock price go in 2025Breakout stock performance - jammulinksnews.com

12:30 PM

Jul 23, 2025

What analysts say about Merus N.V. stockDynamic growth stocks - jammulinksnews.com

Jul 23, 2025

Jul 22, 2025

Merus N.V. Stock Analysis and ForecastPowerful market insights - jammulinksnews.com

Jul 22, 2025

Jul 21, 2025

What drives Merus N.V. stock pricePhenomenal trading returns - Autocar Professional

Jul 21, 2025

Jul 20, 2025

Is Merus N.V. a good long term investmentRapidly expanding wealth - Autocar Professional

Jul 20, 2025

Jul 18, 2025

Merus Shares Soar 3.24% On Positive Cancer Study Update - AInvest

Jul 18, 2025

Jul 18, 2025

Merus NV stock hits all-time high, reaching 62.98 USD - Investing.com

Jul 18, 2025

Jul 17, 2025

Merus Shares Surge Amid Promising Cancer Study - TipRanks

Jul 17, 2025

Jul 17, 2025

Merus N.V. Advances in Head and Neck Cancer Treatment with Phase 3 Study - TipRanks

Jul 17, 2025

Jul 17, 2025

Learn to Evaluate (MRUS) using the Charts - news.stocktradersdaily.com

Jul 17, 2025

Jul 17, 2025

Merus N.V. (NASDAQ:MRUS) Shares Sold by Teacher Retirement System of Texas - Defense World

Jul 17, 2025

Jul 16, 2025

Merus N.V. (NASDAQ:MRUS) Given Average Rating of “Buy” by Analysts - Defense World

Jul 16, 2025

Jul 16, 2025

Why Merus N.V. stock attracts strong analyst attentionFree Access to Community - Newser

Jul 16, 2025

Jul 15, 2025

How Merus N.V. stock performs during market volatilitySwing Trade Signals - newser.com

Jul 15, 2025

Jul 15, 2025

Merus (MRUS) Gets a Buy from H.C. Wainwright - The Globe and Mail

Jul 15, 2025

Jul 15, 2025

What makes Merus N.V. stock price move sharplyAlpha Stock Ideas - Newser

Jul 15, 2025

Jul 14, 2025

Insider Selling: Merus N.V. (NASDAQ:MRUS) COO Sells $924,275.00 in Stock - Defense World

Jul 14, 2025

Jul 12, 2025

Merus (NASDAQ:MRUS) Upgraded by Wall Street Zen to Hold Rating - Defense World

Jul 12, 2025

Jul 11, 2025

MRUS Stock Soars 30% in 3 Months After Phase II Cancer Study Success - sharewise.com

Jul 11, 2025

Jul 09, 2025

Merus, Bicara Present Promising HNSCC Trial Data at ASCO 2025, Advance Towards Phase III - Insider Monkey

Jul 09, 2025

Jun 29, 2025

Merus N.V. (MRUS): A Breakthrough in Oncology with Petosemtamab's ASCO-Backed Potential - AInvest

Jun 29, 2025

Jun 26, 2025

Merus N.V.’s Promising Phase 3 Study in Head and Neck Cancer: What Investors Need to Know - TipRanks

Jun 26, 2025

Jun 18, 2025

Merus gains after mid-stage trial data for lead asset in head and neck cancer - MSN

Jun 18, 2025

Jun 15, 2025

(MRUS) Technical Data - news.stocktradersdaily.com

Jun 15, 2025

Jun 14, 2025

Merus N.V.’s SWOT analysis: promising antibody platform drives stock potential - Investing.com India

Jun 14, 2025

Jun 13, 2025

Merus N.V.’s SWOT analysis: promising antibody platform drives stock potential By Investing.com - Investing.com South Africa

Jun 13, 2025

Jun 11, 2025

Bicara Therapeutics Looks To Reclaim Some Of The Spotlight From Merus (NASDAQ:BCAX) - Seeking Alpha

Jun 11, 2025

Jun 10, 2025

The Netherlands: Merus raises US$300m from underwritten public offering - Investors in Healthcare

Jun 10, 2025

Jun 08, 2025

Why Merus N.V. (MRUS) Crashed On Wednesday - MSN

Jun 08, 2025

Jun 05, 2025

Merus N.V. announces proposed public offering of common shares - MSN

Jun 05, 2025

Jun 05, 2025

Merus dips 7%, prices $300M stock at $57 per share - MSN

Jun 05, 2025

Jun 05, 2025

Merus Announces Public Offering of Common Shares - TipRanks

Jun 05, 2025